<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04073797</url>
  </required_header>
  <id_info>
    <org_study_id>A095007 (PIILL)</org_study_id>
    <nct_id>NCT04073797</nct_id>
  </id_info>
  <brief_title>PET Imaging of Inflammation and Lipid Lowering Study</brief_title>
  <acronym>PIILL</acronym>
  <official_title>PET Imaging of Inflammation and Lipid Lowering Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Cambridge</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cambridge University Hospitals NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wellcome Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Cambridge</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      While 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) imaging has been used&#xD;
      as an early marker of drug efficacy in numerous clinical cardiovascular drug trials, as a&#xD;
      glucose analog, its signal in the vasculature lacks inflammatory cell-specificity. Moreover,&#xD;
      high background 18F-FDG signals from the myocardium often preclude coronary artery imaging,&#xD;
      despite attempts to suppress myocardial tracer uptake by dietary manipulation. These&#xD;
      limitations of 18F-FDG for measuring changes in vascular inflammation arising from drug&#xD;
      intervention highlight important unmet needs, which might be overcome by using a somatostatin&#xD;
      receptor subtype-2 (SST2) PET tracer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Up-regulation of SST2 in activated macrophages represents a novel imaging target for&#xD;
      measuring vascular inflammation, which has been previously examined in atherosclerosis using&#xD;
      68Ga-DOTATATE. To test the hypothesis that 68Ga-DOTATATE can quantify drug-induced changes in&#xD;
      arterial inflammation, patients with stable cardiovascular disease or heterozygous familial&#xD;
      hypercholesterolemia (HeFH) and elevated low density lipoprotein (LDL) cholesterol despite&#xD;
      high-intensity statin treatment will undergo serial carotid 68Ga-DOTATATE PET-magnetic&#xD;
      resonance imaging (MRI) in a double-blind, two-arm, parallel-design, placebo-controlled&#xD;
      study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 20, 2021</start_date>
  <completion_date type="Anticipated">March 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Double-blind, placebo controlled.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Carotid 68Ga-DOTATATE PET</measure>
    <time_frame>12 weeks</time_frame>
    <description>Relative change from baseline in carotid artery 68Ga-DOTATATE tissue-to-blood ratio in the index vessel</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Carotid 68Ga-DOTATATE vs. MRI</measure>
    <time_frame>12 weeks</time_frame>
    <description>Comparison of carotid artery 68Ga-DOTATATE imaging to changes in plaque morphology assessed by high-resolution carotid MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Carotid 68Ga-DOTATATE vs. serum lipids</measure>
    <time_frame>12 weeks</time_frame>
    <description>Comparison of carotid 68Ga-DOTATATE imaging to serum lipids</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Carotid 68Ga-DOTATATE vs. hsCRP</measure>
    <time_frame>12 weeks</time_frame>
    <description>Comparison of carotid 68Ga-DOTATATE imaging to high-sensitivity C-reactive protein (hsCRP)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">56</enrollment>
  <condition>Hypercholesterolemia</condition>
  <condition>Hypercholesterolemia, Familial</condition>
  <arm_group>
    <arm_group_label>Stable CVD - treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Stable CVD with elevated LDL cholesterol despite high-intensity atorvastatin, randomised to add on therapy with a PCSK9 inhibitor</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Stable CVD - placebo control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Stable CVD with elevated LDL cholesterol despite high-intensity atorvastatin, randomised to placebo control</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HeFH - treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HeFH and elevated LDL cholesterol despite high-intensity atorvastatin, randomised to add on therapy with a PCSK9 inhibitor</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HeFH - placebo control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>HeFH and elevated LDL cholesterol despite high-intensity atorvastatin, randomised to placebo control</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PCSK9 inhibitor</intervention_name>
    <description>PCSK9 inhibitor</description>
    <arm_group_label>HeFH - treatment</arm_group_label>
    <arm_group_label>Stable CVD - treatment</arm_group_label>
    <other_name>Alirocumab</other_name>
    <other_name>Evolocumab</other_name>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>68Ga-DOTATATE PET-MRI</intervention_name>
    <description>68Ga-DOTATATE PET-MRI at baseline and 12 weeks</description>
    <arm_group_label>HeFH - placebo control</arm_group_label>
    <arm_group_label>HeFH - treatment</arm_group_label>
    <arm_group_label>Stable CVD - placebo control</arm_group_label>
    <arm_group_label>Stable CVD - treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female participants &gt;18 years old&#xD;
&#xD;
          -  Able to give written, informed consent and to lie flat&#xD;
&#xD;
          -  Have a history of CVD (acute coronary syndrome, ischaemic stroke, transient ischaemic&#xD;
             attack, or documented coronary, carotid, or peripheral arterial disease) and elevated&#xD;
             LDL cholesterol despite high-intensity atorvastatin (Group 1), or&#xD;
&#xD;
          -  Have HeFH (definite or probable FH based on clinical criteria) and elevated LDL&#xD;
             cholesterol despite high-intensity atorvastatin (Group 2)&#xD;
&#xD;
          -  Lipid lowering therapy unchanged for at least 6 weeks prior to screening&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women of child bearing potential not using adequate contraception&#xD;
&#xD;
          -  Contra-indication to MRI scanning&#xD;
&#xD;
          -  Statin-associated myositis or liver function abnormality&#xD;
&#xD;
          -  Sensitivity to PCSK9 inhibitors or monoclonal antibodies&#xD;
&#xD;
          -  Contrast allergy or contrast-nephropathy&#xD;
&#xD;
          -  Chronic kidney disease (eGFR &lt;30 mL/min/1.73 m2)&#xD;
&#xD;
          -  Cardiovascular event within 6 months&#xD;
&#xD;
          -  Any medical condition, in the opinion of the investigator, that prevents the&#xD;
             participant from lying flat during scanning, or from participating in the study&#xD;
&#xD;
          -  Uncontrolled chronic inflammatory disorder&#xD;
&#xD;
          -  History of recent malignancy deemed relevant to the study by the investigator&#xD;
&#xD;
          -  Treatment with medications that result in significant drug to drug interactions with&#xD;
             the study medication&#xD;
&#xD;
          -  Current use of systemic corticosteroids&#xD;
&#xD;
          -  Previous carotid endarterectomy surgery or stenting&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jason M Tarkin, MBBS PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Cambridge</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jason M Tarkin, MBBS PhD</last_name>
    <phone>+44(0)1223331504</phone>
    <email>jt545@cam.ac.uk</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Cambridge</name>
      <address>
        <city>Cambridge</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jason M Tarkin, MBBS PhD</last_name>
      <phone>+44(0)1223331504</phone>
      <email>jt545@cam.ac.uk</email>
    </contact>
    <investigator>
      <last_name>James HF Rudd, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <reference>
    <citation>Tarkin JM, Joshi FR, Evans NR, Chowdhury MM, Figg NL, Shah AV, Starks LT, Martin-Garrido A, Manavaki R, Yu E, Kuc RE, Grassi L, Kreuzhuber R, Kostadima MA, Frontini M, Kirkpatrick PJ, Coughlin PA, Gopalan D, Fryer TD, Buscombe JR, Groves AM, Ouwehand WH, Bennett MR, Warburton EA, Davenport AP, Rudd JH. Detection of Atherosclerotic Inflammation by (68)Ga-DOTATATE PET Compared to [(18)F]FDG PET Imaging. J Am Coll Cardiol. 2017 Apr 11;69(14):1774-1791. doi: 10.1016/j.jacc.2017.01.060.</citation>
    <PMID>28385306</PMID>
  </reference>
  <reference>
    <citation>Pedersen SF, Sandholt BV, Keller SH, Hansen AE, Clemmensen AE, Sillesen H, Højgaard L, Ripa RS, Kjær A. 64Cu-DOTATATE PET/MRI for Detection of Activated Macrophages in Carotid Atherosclerotic Plaques: Studies in Patients Undergoing Endarterectomy. Arterioscler Thromb Vasc Biol. 2015 Jul;35(7):1696-703. doi: 10.1161/ATVBAHA.114.305067. Epub 2015 May 14.</citation>
    <PMID>25977567</PMID>
  </reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 27, 2019</study_first_submitted>
  <study_first_submitted_qc>August 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 29, 2019</study_first_posted>
  <last_update_submitted>August 20, 2021</last_update_submitted>
  <last_update_submitted_qc>August 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Cambridge</investigator_affiliation>
    <investigator_full_name>Jason Tarkin</investigator_full_name>
    <investigator_title>Wellcome Clinical Research Career Development Fellow &amp; Clinical Lecturer</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperlipoproteinemia Type II</mesh_term>
    <mesh_term>Hypercholesterolemia</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Evolocumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

